Accelerating Innovation at Leica Biosystems

Portfolio Indexed to Most Attractive Areas of Diagnostics BEST IN CLASS MOLECULAR DX SCALED "NICHE" POSITIONS Largest installed base & test menu, COVID-19 Cepheid. +LDD core growth* Leica BIOSYSTEMS RADIOMETERER Each >$1B annual revenue +HSD core growth* PRODUCT LINE REVENUE & GROWTH RATES +MSD/HSD* >40% OF REV. STRONG CORE LAB PRESENCE BECKMAN COULTER *Core revenue growth rates reflect anticipated mid/long-term growth Pie chart reflects FY 2021E revenue by product line A leading player +MSD core growth* Acute POC Immuno- assay Pathology Other Molecular Hem. & Urinalysis +LDD* Clinical >30% OF REV. +LSD* Chemistry 25% OF REV. Comprehensive portfolio with strong footholds across Dx landscape DANAHER

View entire presentation